Short-Term Drug-Drug Interaction between Sildenafil and Bosentan under Long-Term Use in Patients with Pulmonary Arterial Hypertension


Sildenafil and bosentan are often co-administered for pulmonary arterial hypertension (PAH) treatment. The plasma concentration of sildenafil can be decreased by half if co-administered with bosentan. Many patients take these agents simultaneously in the morning and the evening. The aim of this study was to examine the pharmacokinetics of sildenafil which was interfered with bosentan administration to ascertain whether these agents should be given concomitantly or separately. A two-way crossover study was conducted in 6 PAH patients with combination therapy of sildenafil and bosentan. Participants underwent the sequence of treatment phases: phase S (sildenafil administered 3 h before bosen-tan); phase B (bosentan administered 3 h before sildenafil); and phase C (administered concomitantly). Blood samples were collected on the last day of each phase. There was no significant difference in maximum plasma concentration or area under the plasma concentration-time curve (AUC0-8) between phase C and phase S (95.5 ± 24.8 vs. 72.9 ± 40.9 (p = 0.07), 209.7 ± 81.8 vs. 180.2 ± 126.4 (p = 0.24), respectively) or between phases C and B (87.8 ± 42.0 vs. 99.6 ± 33.9 (p = 0.59), 197.2 ± 88.2 vs. 240.7 ± 121.8 (p = 0.19), respectively) (ng/mL, mean ± standard deviation). Large intra-and inter-individual variability in sildenafil concentration was noted. The timing of administration of sildenafil and bosentan does not significantly influence the plasma concentration of sildenafil. Physicians do not need to be overly concerned about the timing of administration of these drugs to maximize the sildenafil concentration.

Share and Cite:

S. Miyakawa, K. Odagiri, N. Inui, A. Hakamata, T. Goto, S. Tanaka, S. Uchida, N. Namiki and H. Watanabe, "Short-Term Drug-Drug Interaction between Sildenafil and Bosentan under Long-Term Use in Patients with Pulmonary Arterial Hypertension," Pharmacology & Pharmacy, Vol. 4 No. 7, 2013, pp. 542-548. doi: 10.4236/pp.2013.47078.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. Humbert, O. Sitbon and G. Simonneau, “Treatment of Pulmonary Arterial Hypertension,” The New England Journal of Medicine, Vol. 351, No. 14, 2004, pp. 1425-1436.
[2] J. R. Runo and J. E. Loyd, “Primary Pulmonary Hypertension,” The Lancet, Vol. 361, No. 9368, 2003, pp. 1533-1544.
[3] G. E. D’Alonzo, R. J. Barst, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, et al., “Survival in Patients with Primary Pulmonary Hypertension. Results from a National Prospective Registry,” Annals of International Medicine, Vol. 115, No. 5, 1991, pp. 343-349.
[4] R. L. Benza, D. P. Miller, M. Gomberg-Maitland, R. P. Frantz, A. J. Foreman, C. S. Coffey, et al., “Predicting Survival in Pulmonary Arterial Hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (Reveal),” Circulation, Vol. 122, No. 2, 2010, pp. 164-172.
[5] M. Humbert, O. Sitbon, A. Chaouat, M. Bertocchi, G. Habib, V. Gressin, et al., “Survival in Patients with Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era,” Circulation, Vol. 122, No. 2, 2010, pp. 156-163.
[6] G. W. Mikhail, S. K. Prasad, W. Li, P. Rogers, A. H. Chester, S. Bayne, et al., “Clinical and Haemodynamic Effects of Sildenafil in Pulmonary Hypertension: Acute and Mid-Term Effects,” European Heart Journal, Vol. 25, No. 5, 2004, pp. 431-436.
[7] R. N. Channick, G. Simonneau, O. Sitbon, I. M. Robbins, A. Frost, V. F. Tapson, et al., “Effects of the Dual Endothelin-Receptor Antagonist Bosentan in Patients with Pulmonary Hypertension: A Randomised Placebo-Controlled Study,” The Lancet, Vol. 358, No. 9288, 2001, pp. 1119-1123.
[8] L. J. Rubin, D. B. Badesch, R. J. Barst, N. Galie, C. M. Black, A. Keogh, et al., “Bosentan Therapy for Pulmonary Arterial Hypertension,” The New England Journal of Medicine, Vol. 346, No. 12, 2002, pp. 896-903.
[9] H. A. Ghofrani, O. Distler, F. Gerhardt, M. Gorenflo, E. Grunig, W. E. Haefeli, et al., “Treatment of Pulmonary Arterial Hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011,” International Journal of Cardiology, Vol. 154, Suppl. 1, 2011, pp. S20-S33.
[10] G. A. Paul, J. S. Gibbs, A. R. Boobis, A. Abbas and M. R. Wilkins, “Bosentan Decreases the Plasma Concentration of Sildenafil When Coprescribed in Pulmonary Hypertension,” British Journal of Clinical Pharmacology, Vol. 60, No. 1, 2005, pp. 107-112.
[11] N. Galie, H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, et al., “Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension,” The New England Journal of Medicine, Vol. 353, No. 20, 2005, pp. 2148-2157.
[12] G. Burgess, H. Hoogkamer, L. Collings and J. Dingemanse, “Mutual Pharmacokinetic Interactions between Steady-State Bosentan and Sildenafil,” European Journal of Clinical Pharmacology, Vol. 64, No. 1, 2008, pp. 43-50.
[13] P. L. van Giersbergen, C. Gnerre, A. Treiber, J. Dingemanse and U. A. Meyer, “Bosentan, a Dual Endothelin Receptor Antagonist, Activates the Pregnane X Nuclear Receptor,” European Journal of Pharmacology, Vol. 450, No. 2, 2002, pp. 115-121.
[14] R. Hyland, E. G. Roe, B. C. Jones and D. A. Smith, “Identification of the Cytochrome P450 Enzymes Involved in the N-Demethylation of Sildenafil,” British Journal of Clinical Pharmacology, Vol. 51, No. 3, 2001, pp. 239-248.
[15] J. Dingemanse and P. L. van Giersbergen, “Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist,” Clinical Pharmacokinetics, Vol. 43, No. 15, 2004, pp. 1089-1115.
[16] A. Viger-Chougnet, C. Funk and M. Pantze, “Drug-Drug Interactions with Bosentan (Ro 47-0203): In Vitro Studies of the Inhibition Potential of Bosentan on the Main Human Cytochrome P450 Isoenzymes,” 1997.
[17] G. J. Muirhead, D. J. Rance, D. K. Walker and P. Wastall, “Comparative Human Pharmacokinetics and Metabolism of Single-Dose Oral and Intravenous Sildenafil,” British Journal of Clinical Pharmacology, Vol. 53, Suppl. 1, 2002, pp. 13S-20S.
[18] A. Treiber, R. Schneiter, S. Hausler and B. Stieger, “Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil,” Drug Metabolism and Disposition, Vol. 35, No. 8, 2007, pp. 1400-1407.
[19] A. Treiber, R. Schneiter, S. Delahaye and M. Clozel, “Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 308, No. 3, 2004, pp. 1121-1129.
[20] Pfizer, “Revatio (Sildenafil) Tablets,” 1998.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.